Asia
Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates regarding its in-house discovered lenvatinib mesylate, eribulin mesylate, and MORAb-202 will be given at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from May 31 to June 4, 2019.
Teijin Limited announced today its establishment of NOMON, Co., Ltd. to sell nutraceutical food and beverages that are scientifically proven to help people maintain their health.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
Pharma and biotech companies from across the globe provide business and pipeline updates, with news from Gecko, ValGenesis, NeuClone, Zymeworks, and more.
The panel opposed approval of Daiichi Sankyo’s AML drug but supported approval for its TGCT treatment.
Teijin Limited announced today that it has signed a research and development agreement with the Japan Agency for Medical Research and Development (AMED) to form an industry-government-academia partnership that will explore preventive and therapeutic drugs for frail elderly people as designated under AMED’s Cyclic Innovation for Clinical Empowerment program(CiCLE) in October 2018.
Researchers with the RIKEN Center for Brain Science and Ochanomizu University evaluated a treatment for stroke that appears to decrease the damage to the brain. The scientists studied the approach in mice.
Eisai Co., Ltd. announced today that it has entered into a license agreement with medac Gesellschaft fur klinische Spezialpraparate mbH for the commercialization of its anti-rheumatic agent methotrexate (MTX) subcutaneous injection (pre-filled syringe) in Japan.
For Upcoming Clinical Studies on Prevention of Alzheimer’s Disease
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
PRESS RELEASES